Drug Profile
Human fibrinogen - Shanxi Kangbao Biological Product
Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator Shanxi Kangbao Biological Product
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Afibrinogenaemia
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Afibrinogenaemia in China (IV)
- 15 Jan 2016 Clinical trials in Afibrinogenaemia in China (IV) prior to January 2016 (Shanxi Kangbao Biological Product pipeline, January 2016)